GSWM
TCRT icon

Golden State Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Golden State Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-604
Closed -$297K – 482
2020
Q2 		$297K Buy
+604
New +$269K 0.08% 171

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Golden State Wealth Management's TCRT Position: Q3 2020 in Review

Golden State Wealth Management sold out of Alaunos Therapeutics (TCRT) in Q3 2020, closing a stake of 604 shares — an estimated $297K sold.

Golden State Wealth Management first reported a position in TCRT in Q2 2020 and held it in 1 quarter. The position peaked at $297K in Q2 2020. 154 funds tracked by Wall St. Rank hold TCRT as of Q3 2020.

  • Golden State Wealth Management reported no remaining Alaunos Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Golden State Wealth Management sold 604 Alaunos Therapeutics shares in Q3 2020, an estimated $297K.
  • Golden State Wealth Management first reported a position in Alaunos Therapeutics in Q2 2020 and held it in 1 quarter.
  • Golden State Wealth Management's Alaunos Therapeutics position peaked at $297K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2020.

Based on Golden State Wealth Management's 13F filing for Q3 2020, filed 12 Nov 2020.